{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:43:38Z","timestamp":1792262618428,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2022-YXZX-MY-03"],"award-info":[{"award-number":["2022-YXZX-MY-03"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["H2023087"],"award-info":[{"award-number":["H2023087"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330055"],"award-info":[{"award-number":["82330055"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231119"],"award-info":[{"award-number":["BK20231119"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04237-1","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T18:59:21Z","timestamp":1741546761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Wenyi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"4237_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2023;401:304\u201318.","journal-title":"Lancet"},{"key":"4237_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis. 2007;66:940\u20134.","journal-title":"Ann Rheum Dis"},{"key":"4237_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708\u201319.","journal-title":"Lancet Respir Med"},{"key":"4237_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8:963\u201374.","journal-title":"Lancet Respir Med"},{"key":"4237_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10067-019-04784-y","volume":"39","author":"L Yang","year":"2020","unstructured":"Yang L, Wang Q, Hou Y, et al. The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. Clin Rheumatol. 2020;39:813\u201321.","journal-title":"Clin Rheumatol"},{"key":"4237_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/ard-2023-223859","volume":"82","author":"P Chitturi","year":"2023","unstructured":"Chitturi P, Xu S, Ahmed Abdi B, et al. Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Ann Rheum Dis. 2023;82:1191\u2013204.","journal-title":"Ann Rheum Dis"},{"key":"4237_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12016-021-08892-z","volume":"64","author":"X Zhuang","year":"2023","unstructured":"Zhuang X, Hu X, Zhang S, Li X, Yuan X, Wu Y. Mesenchymal stem cell-based therapy as a new approach for the treatment of systemic sclerosis. Clin Rev Allergy Immunol. 2023;64:284\u2013320.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4237_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40257-023-00831-2","volume":"25","author":"N Teske","year":"2024","unstructured":"Teske N, Fett N. Recent advances in treatment of systemic sclerosis and morphea. Am J Clin Dermatol. 2024;25:213\u201326.","journal-title":"Am J Clin Dermatol"},{"key":"4237_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13287-023-03543-w","volume":"14","author":"H Yang","year":"2023","unstructured":"Yang H, Cheong S, He Y, Lu F. Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease. Stem Cell Res Ther. 2023;14:372.","journal-title":"Stem Cell Res Ther"},{"key":"4237_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/cr.2017.11","volume":"27","author":"C Chen","year":"2017","unstructured":"Chen C, Wang D, Moshaverinia A, et al. Mesenchymal stem cell transplantation in tight-skin mice identifies miR-151-5p as a therapeutic target for systemic sclerosis. Cell Res. 2017;27:559\u201377.","journal-title":"Cell Res"},{"key":"4237_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/rheumatology\/kev323","volume":"55","author":"P Guillaume-Jugnot","year":"2016","unstructured":"Guillaume-Jugnot P, Daumas A, Magalon J, et al. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology (Oxford). 2016;55:301\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"4237_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-017-1373-2","volume":"19","author":"H Zhang","year":"2017","unstructured":"Zhang H, Liang J, Tang X, et al. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther. 2017;19:165.","journal-title":"Arthritis Res Ther"},{"key":"4237_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10067-024-06865-z","volume":"43","author":"M Alip","year":"2024","unstructured":"Alip M, Wang D, Zhao S, et al. Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study. Clin Rheumatol. 2024;43:1073\u201382.","journal-title":"Clin Rheumatol"},{"key":"4237_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"4237_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"4237_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/273291","volume":"2012","author":"D Wang","year":"2012","unstructured":"Wang D, Akiyama K, Zhang H, et al. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol. 2012;2012: 273291.","journal-title":"Clin Dev Immunol"},{"key":"4237_CR17","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573\u20136.","journal-title":"J Rheumatol"},{"key":"4237_CR18","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.2147\/JIR.S373387","volume":"15","author":"H Cheng","year":"2022","unstructured":"Cheng H, Yu Z, Yan CL, Yang HD, Gao C, Wen HY. Long-term efficacy and low adverse events of methylprednisolone pulses combined to low-dose glucocorticoids for systemic sclerosis: a retrospective clinical study of 10 years\u2019 follow-up. J Inflamm Res. 2022;15:4421\u201333.","journal-title":"J Inflamm Res"},{"key":"4237_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, et al. An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"4237_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.brat.2017.01.005","volume":"98","author":"J Lee","year":"2017","unstructured":"Lee J, Little TD. A practical guide to propensity score analysis for applied clinical research. Behav Res Ther. 2017;98:76\u201390.","journal-title":"Behav Res Ther"},{"key":"4237_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"4237_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","volume":"23","author":"S Jaafar","year":"2021","unstructured":"Jaafar S, Lescoat A, Huang S, et al. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther. 2021;23:170.","journal-title":"Arthritis Res Ther"},{"key":"4237_CR23","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s10067-018-4171-6","volume":"37","author":"WMT van den Hombergh","year":"2018","unstructured":"van den Hombergh WMT, Simons SO, Teesselink E, et al. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. Clin Rheumatol. 2018;37:2715\u201322.","journal-title":"Clin Rheumatol"},{"key":"4237_CR24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","volume":"46","author":"RE Pellar","year":"2017","unstructured":"Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum. 2017;46:767\u201374.","journal-title":"Semin Arthritis Rheum"},{"key":"4237_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.molimm.2023.03.017","volume":"157","author":"L Xie","year":"2023","unstructured":"Xie L, Long X, Mo M, et al. Bone marrow mesenchymal stem cell-derived exosomes alleviate skin fibrosis in systemic sclerosis by inhibiting the IL-33\/ST2 axis via the delivery of microRNA-214. Mol Immunol. 2023;157:146\u201357.","journal-title":"Mol Immunol"},{"key":"4237_CR26","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","volume":"4","author":"D Farge","year":"2022","unstructured":"Farge D, Loisel S, Resche-Rigon M, et al. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study. Lancet Rheumatol. 2022;4:e91\u2013104.","journal-title":"Lancet Rheumatol"},{"key":"4237_CR27","doi-asserted-by":"publisher","first-page":"7061408","DOI":"10.1155\/2019\/7061408","volume":"2019","author":"L Wen","year":"2019","unstructured":"Wen L, Labopin M, Badoglio M, Wang D, Sun L, Farge-Bancel D. Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells. Stem Cells Int. 2019;2019:7061408.","journal-title":"Stem Cells Int"},{"key":"4237_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","volume":"9","author":"J Liang","year":"2018","unstructured":"Liang J, Zhang H, Kong W, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018;9:312.","journal-title":"Stem Cell Res Ther"},{"key":"4237_CR29","doi-asserted-by":"publisher","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","volume":"62","author":"M Kreuter","year":"2023","unstructured":"Kreuter M, Hoffmann-Vold AM, Matucci-Cerinic M, et al. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2023;62:SI43\u201353.","journal-title":"Rheumatology (Oxford)"},{"key":"4237_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13075-018-1735-4","volume":"20","author":"S Hu","year":"2018","unstructured":"Hu S, Hou Y, Wang Q, Li M, Xu D, Zeng X. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. Arthritis Res Ther. 2018;20:235.","journal-title":"Arthritis Res Ther"},{"key":"4237_CR31","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"4237_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1378\/chest.14-0793","volume":"146","author":"DB Taichman","year":"2014","unstructured":"Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146:449\u201375.","journal-title":"Chest"},{"key":"4237_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1183\/09031936.00194810","volume":"37","author":"N Galie","year":"2011","unstructured":"Galie N, Hoeper MM, Gibbs JS, Simonneau G. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J. 2011;37:475\u20136.","journal-title":"Eur Respir J"},{"key":"4237_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-023-03063-1","volume":"25","author":"G Nagy","year":"2023","unstructured":"Nagy G, Dobrota R, Becker MO, et al. Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis. Arthritis Res Ther. 2023;25:84.","journal-title":"Arthritis Res Ther"},{"key":"4237_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jot.2024.07.005","volume":"48","author":"J Wu","year":"2024","unstructured":"Wu J, Wu J, Liu Z, et al. Mesenchymal stem cell-derived extracellular vesicles in joint diseases: therapeutic effects and underlying mechanisms. J Orthop Translat. 2024;48:53\u201369.","journal-title":"J Orthop Translat"},{"key":"4237_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41525-022-00327-8","volume":"7","author":"M Kerick","year":"2022","unstructured":"Kerick M, Acosta-Herrera M, Simeon-Aznar CP, et al. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis. NPJ Genom Med. 2022;7:57.","journal-title":"NPJ Genom Med"},{"key":"4237_CR37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-021-01141-y","volume":"14","author":"Z Weng","year":"2021","unstructured":"Weng Z, Zhang B, Wu C, et al. Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer. J Hematol Oncol. 2021;14:136.","journal-title":"J Hematol Oncol"},{"key":"4237_CR38","doi-asserted-by":"publisher","first-page":"103167","DOI":"10.1016\/j.autrev.2022.103167","volume":"21","author":"C Carbonell","year":"2022","unstructured":"Carbonell C, Marcos M, Guillen-Del-Castillo A, et al. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: data from the spanish scleroderma registry (RESCLE). Autoimmun Rev. 2022;21:103167.","journal-title":"Autoimmun Rev"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04237-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:07:59Z","timestamp":1741601279000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04237-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4237"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04237-1","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"(1) Title of the approved project: Clinical study of umbilical cord mesenchymal stem cell transplantation in the treatment of autoimmune diseases; (2) Name of the institutional approval committee or unit: Nanjing Drum Tower Hospital Affiliated to Nanjing University School of Medicine; (3) Approval number: 2009004; (4) Date of approval: January 9, 2009. Because this study is a retrospective study, it is approved by the ethics committee and does not require informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that the research project was not conducted under any circumstances where they had a potential commercial or financial conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}